Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q1 2020 · 10-Q
Revenue$1.13M$1.13M+72.8% vs Q1 2019 Net Income-$2.08M-$2.08MN/M vs Q1 2019 EPS Diluted-$0.22-$0.22N/M vs Q1 2019 Operating Income-$2,369,558N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
Margins · derivedOperating margin-209.2%+24.6 pt vs Q1 2019
Net margin-183.9%+48.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 14, 2020 · 44 d after period end